Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.
 
Home / Learn / Oncology Pharmacy / View All Insights

View All Insights

This OPEN Oncology Pharmacy Insights series highlights essential takeaways from panel discussions comprising a pre-conference to the ACCC National Oncology Conference in 2018. Sessions brought together perspectives from oncology pharmacist leaders and cancer program financial advocacy professionals with experience in helping patients mitigate the economic burden of cancer. The range of topics across these Oncology Pharmacy Insights reflects the rapidly changing oncology therapeutic environment. 

 

  • Integrating Oral Oncolytics into Pharmacy Practice
    Jul 12, 2019
    Indications are oral oncolytics will play an increasingly prominent role in the treatment of a number of cancers. The pharmacy team is ideally positioned to optimize patient access and adherence to oral therapies. Operationalizing requires proactive steps to assess workflow, standardize processes, efficiently manage preauthorizations and more.
  • Multidisciplinary Molecular Tumor Boards: Two Models
    Jun 28, 2019
    Molecular tumor boards offer a vital resource to support delivery of precision medicine to oncology patients. Various members of the cancer care team should be represented, including the oncology pharmacist.
  • Facilitating Access to Cancer Immunotherapies
    May 9, 2019
    Access to new cancer immunotherapies is important for patients in an increasing number of cancers. Integrating costly paradigm-changing treatments into practice requires expertise from the oncology pharmacist working closely with administration, oncology nursing, and new team members such as oncology financial navigators.
  • Town Hall: Care Coordination and Financial Advocacy
    May 9, 2019
    In October 2018, the Association of Community Cancer Centers (ACCC) hosted a pre-conference workshop at its 35th National Oncology Conference to review how oncology pharmacists can best respond to rapid changes in the oncology environment, including the increasing need for a coordinated approach to financial advocacy and navigation.
  • Integrating Biosimilars Within a Community, Academic, or Health-System Setting
    May 9, 2019
    Biosimilars offer the potential for cost savings, for instance, by enhancing competition and reducing patient co-pays and premiums, but many challenges exist which may limit biosimilar development and expected savings in the future. It is incumbent on physician and pharmacy leaders to consider how and where biosimilars can be substituted for reference products to contribute to savings in oncology care.
  • Financial Advocacy in a Value-Based World
    May 9, 2019
    Along with all of the clinical and practical benefits that come with oral oncolytics, these therapies can also present new obstacles to treatment. Oncology pharmacists have proven that they can help address these issues by taking on expanded roles to support the cancer care team, enhance patient options and access to effective treatments, improve patient outcomes, and maximize reimbursement.